At a glance
- Depends onMidstream position: 5 outgoing, 4 incoming connections
- ScaleLevered free cash flow is $25.67M, above the global median of $18.58M
- FinancialsAltman Z-Score 1.8: grey zone
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.71BCNY323.85M · vs all stocks (USD)
Trailing P/E
69.89xRevenue (TTM)
797.57MCNY127.36M · vs all stocks (USD)
Profit Margin
2.80%Beta
0.5760xvs all stocks
52-Week Change
-39.46%vs all stocks
Market Capitalization
1.71BCNY323.85M · vs all stocks (USD)
Enterprise Value
2.06BCNY389.56M · vs all stocks (USD)
Trailing P/E
69.89xForward P/E
10.48xPrice to Sales (TTM)
2.14xPrice to Book (MRQ)
3.23xEnterprise to Revenue
2.58xEnterprise to EBITDA
15.45xGross Margin
65.84%Profit Margin
2.80%Operating Margin
10.34%Return on Assets (TTM)
3.30%Return on Equity (TTM)
6.49%Revenue (TTM)
797.57MCNY127.36M · vs all stocks (USD)
Revenue per Share (TTM)
3.26CNYUpdated Nov 22, 2026Quarterly Revenue Growth
-21.80%Gross Profit (TTM)
518.04MCNY83.97M · vs all stocks (USD)
EBITDA (TTM)
189.81MCNY28.45M · vs all stocks (USD)
Net Income (TTM)
22.33MCNY4.31M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
-29.30%Operating Cash Flow (TTM)
147.31MCNY23.29M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
98.67MCNY25.67M · vs all stocks (USD)
5-Year Average Dividend Yield
0.36%vs all stocks
Payout Ratio
0.00%Minority Interest (Equity)
289.70MCNYFY2025 · Dec 31, 2025Revenue
870.79MCNYFY2025 · Dec 31, 2025Cost of Goods Sold
284.04MCNYFY2025 · Dec 31, 2025Gross Profit
586.75MCNYFY2025 · Dec 31, 2025Operating Income
115.35MCNY17.29M · vs all stocks (USD)
Pre-tax Income
90.79MCNYFY2025 · Dec 31, 2025Income Tax Expense
34.36MCNYFY2025 · Dec 31, 2025Net Income
56.44MCNYFY2025 · Dec 31, 2025EBIT
112.43MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
189.81MCNYFY2025 · Dec 31, 2025Research & Development
50.80MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
251.90MCNYFY2025 · Dec 31, 2025Other Operating Expenses
11.88MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
245.51KCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
21.63MCNYFY2025 · Dec 31, 2025EPS (Basic)
0.1024CNYFY2025 · Dec 31, 2025EPS (Diluted)
0.1015CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
242.68MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
242.68MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
56.44MCNYFY2025 · Dec 31, 2025Minority Interests (P&L)
-31.59MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
35.43MCNYFY2025 · Dec 31, 2025Free Cash Flow
1.47MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
161.31MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
56.44MCNYFY2025 · Dec 31, 2025Other Non-cash Items
25.08MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-40.67MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-5.42MCNYFY2025 · Dec 31, 2025Capital Expenditures
-33.96MCNYFY2025 · Dec 31, 2025Purchase of Investments
-60.29MCNYFY2025 · Dec 31, 2025Sale of Investments
2.36MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-91.89MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
238.30MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-285.64MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-18.97MCNYFY2025 · Dec 31, 2025Other Financing Charges
73.24MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
6.93MCNYFY2025 · Dec 31, 2025Shares Outstanding
256.06MSharesUpdated Nov 22, 2026Float Shares
216.72MSharesUpdated Nov 22, 2026% Held by Insiders
19.94%vs all stocks
% Held by Institutions
1.66%vs all stocks
Total Cash (MRQ)
134.03MCNY14.51M · vs all stocks (USD)
Total Cash per Share (MRQ)
0.5210CNYUpdated Nov 22, 2026Total Debt (MRQ)
512.77MCNY69.79M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.9145xCurrent Ratio (MRQ)
1.03xBook Value per Share (MRQ)
1.95CNYUpdated Nov 22, 2026Total Assets
1.64BCNY246.21M · vs all stocks (USD)
Total Current Assets
604.06MCNYFY2025 · Dec 31, 2025Total Liabilities
1.05BCNYFY2025 · Dec 31, 2025Total Non-current Assets
1.04BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
431.06MCNYFY2025 · Dec 31, 2025Total Current Liabilities
617.21MCNYFY2025 · Dec 31, 2025Cash
160.98MCNYFY2025 · Dec 31, 2025Cash Equivalents
343.81KCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
161.32MCNYFY2025 · Dec 31, 2025Accounts Receivable
207.28MCNYFY2025 · Dec 31, 2025Inventory
132.91MCNYFY2025 · Dec 31, 2025Accounts Payable
62.83MCNYFY2025 · Dec 31, 2025Short-term Debt
322.38MCNYFY2025 · Dec 31, 2025Other Current Liabilities
5.52MCNYFY2025 · Dec 31, 2025Long-term Debt
238.64MCNYFY2025 · Dec 31, 2025Other Non-current Liabilities
6.57MCNYFY2025 · Dec 31, 2025Common Stock (Book)
256.11MCNYFY2025 · Dec 31, 2025Retained Earnings
-216.31MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
594.33MCNY89.08M · vs all stocks (USD)
Treasury Stock
62.69MCNYFY2025 · Dec 31, 202552-Week Low
6.28CNYUpdated Nov 22, 202652-Week High
15.20CNYUpdated Nov 22, 202652-Week Change
-39.46%vs all stocks
Beta
0.5760xvs all stocks
50-Day MA
8.29CNYUpdated Nov 22, 2026200-Day MA
9.98CNYUpdated Nov 22, 2026Avg 10-Day Volume
5.73MSharesUpdated Nov 22, 2026Avg 30-Day Volume
7.09MSharesUpdated Nov 22, 2026Diluted EPS (TTM)
0.0900CNYUpdated Nov 22, 2026Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.66Profit Margin: 0.03
Financial Health
Altman Z-Score 1.8: grey zoneSignificant
Altman Z-Score: 1.80
Supply Chain
Midstream position: 5 outgoing, 4 incoming connectionsNotable
Outgoing: 5.00Incoming: 4.00
Scale
Levered free cash flow is $25.67M, above the global median of $18.58MNotable
Levered free cash flow (USD): 25,672,075.196Global Median: 18,579,867.004
Companies that share the same coordination system — how they create, deliver, or capture value.
Cuorips Inc.
Tier 1ProductionApproval-Gated PipelineRule
Grape King Bio Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Emergent BioSolutions Inc.
Tier 1ProductionApproval-Gated PipelineRule
Newron Pharmaceuticals SpA
Tier 1ProductionApproval-Gated PipelineRuleRisk
Golden Throat Holdings Group Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Green Cross Holdings Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Enwei Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Dishman Carbogen Amcis Ltd.
Tier 1ProductionApproval-Gated PipelineFlowRule
Jiangsu Cowin Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Tuoxin Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRule